Triple‐negative breast cancer (TNBC)—defined as absence of expression of estrogen receptor (ER) and progesterone receptor (PR) as well as no overexpression of human epidermal growth factor receptor 2 (HER2)—accounts for approximately 10% to 20% of all cases of breast cancer 2. The gene discussed is PGR; the disease is breast carcinoma.